ELACESTRANT MONOTHERAPY VS. STANDARD OF CARE FOR THE TREATMENT OF PATIENTS WITH ER+/HER2- ADVANCED BREAST CANCER FOLLOWING CDK4/6 INHIBITOR THERAPY: A PHASE 3 RANDOMIZED, OPEN-LABEL, ACTIVE CONTROLLED, MULTICENTER TRIAL (EMERALD) CTMS#: 19-0013

Cancer Type

Breast

ClinicalTrials.gov Identifier

ClinicalTrials.gov registration not required

Principal Investigator

Virginia Kaklamani, MD

For more information about this study

View Details